<DOC>
	<DOCNO>NCT02914691</DOCNO>
	<brief_summary>Background : SGLT2 inhibitor first antiglycaemic drug direct renal action . A part reduce blood glucose , systemic blood pressure albuminuria decrease , natriuresis increase . Previous research urinary peptide pattern ( proteomics ) reveal patient risk progressive renal disease display `` risk peptide pattern '' urine , ahead decline renal function . Furthermore urinary proteome pattern relate CVD risk . The long-term impact dapagliflozin ( dapa ) treatment renal parameter unknown , long term randomize trial ongoing . By investigate impact dapa treatment peptide pattern , determine whether intervention improve urinary proteomic peptide pattern . In addition new knowledge regard renal process treatment influence seek . The impact treatment urinary tubular marker oxidative stress function ( metabolomics ) assess . These marker think represent one several deleterious pathway involve pathology diabetic renal disease , impact dapa treatment investigate . Improvement marker oxidative stress may indicate long-term benefit . Objective : The primary objective ass impact three month treatment dapa 10 mg daily placebo renal proteomics pattern risk marker diabetic comorbidity . Design : Double blind , randomize , placebo-controlled crossover , single center study . Treatment period : 2 x 12 week . Patient population : 40 patient type 2 diabetes recruit Steno Diabetes Center accordance study in- exclusion criterion . Intervention : Dapa 10 mg daily vs. placebo . Endpoints : Primary outcome : To evaluate effect dapa treatment urinary proteomic pattern patient type 2 diabetes , microalbuminuria eGFR equal 45 ml/min/1.73m2 . Secondary endpoint effect intervention marker tubular function , inflammation , endothelial dysfunction , microcirculation , kidney function , albuminuria , vasoactive hormone plasma , effect global longitudinal strain measure echocardiography . Timeframe : Randomisation plan June 2015 , inclusion follow 9 month . Last patient expect complete October 2016 . Data analysis complete December 2016 , presentation autumn 2017 publication early 2018 .</brief_summary>
	<brief_title>Effects Dapagliflozin Treatment Urinary Proteomic Patterns Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<criteria>Male female patient &gt; 18 year age diagnosis type 2 diabetes ( WHO criteria ) . Patients must current stable antiglycaemic treatment oral drug ( OAD ) insulin 4 week start study drug throughout study duration . Patients must stable antihypertensive treatment ( must include reninangiotensin system block treatment ) 4 week start study drug throughout study duration . HbA1c &gt; 7.5 % Urinary albumin creatinine ratio ( UACR ) &gt; 30 mg/g ( ≥2 3 morning spot urine collection prior randomisation ) . eGFR ≥ 45 ml/min/1.73 m2 Stable RAASblocking treatment ( equal 4 week prior visit 0 ) If stable visit 0 , screen phase prolong 4 week . Current treatment loop diuretic Current treatment thiazolidinediones Current treatment dapagliflozin SGLT2 inhibitor Ongoing cancer treatment Patients hypertension treatment stable antihypertensive treatment ( must include reninangiotensin system block treatment ) 4 week start study drug throughout study duration Severe hepatic insufficiency and/or significant abnormal liver function define aspartate aminotransferase ( AST ) &gt; 3x upper limit normal ( ULN ) and/or alanine aminotransferase ( ALT ) &gt; 3x ULN Total bilirubin &gt; 2.0 mg/dL ( 34.2 µmol/L ) Positive serologic evidence current infectious liver disease include , Hepatitis B surface antigen antibody Hepatitis C virus antibody eGFR : &lt; 45 mL/min ( calculate MDRD formula ) History unstable rapidly progress renal disease Volume deplete patient . Patients risk volume depletion due coexist condition concomitant medication , loop diuretic careful monitoring volume status Recent Cardiovascular Events patient : 1 . Acute Coronary Syndrome ( ACS ) within 2 month prior enrolment 2.Hospitalization unstable angina acute myocardial infarction within 2 month prior enrolment 3 . Acute Stroke TIA within two month prior enrolment 4 . Less two month post coronary artery revascularization Congestive heart failure define New York Heart Association ( NYHA ) class IV , unstable acute congestive heart failure . Note : eligible patient congestive heart failure , especially diuretic therapy , careful monitoring volume status throughout study . Pregnant breastfeeding patient Patients , judgement investigator , may risk dehydration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>Diabetic Nephropathy</keyword>
	<keyword>Proteomics</keyword>
	<keyword>Albuminuria</keyword>
	<keyword>SGLT2 inhibitor</keyword>
</DOC>